| |
Robert Kamen, Ph.D.
Executive-in-Residence
Boston, MA
rkamen@oxbio.com |
Dr. Kamen joined Oxford as an Executive-in-Residence in November 2002. Prior to that, he was president of Abbott Bioresearch Center, Abbott’s immunology/oncology drug discovery and biologics production unit in Worcester, Mass. He served on Abbott Pharmaceutical’s Executive Management Committee. Dr. Kamen joined Abbott subsequent to its acquisition of BASF’s pharmaceutical business in 2001 after serving as BASF Bioresearch Corporation’s president for ten years. Dr. Kamen retired in May 2002, but continues to serve Abbott as senior consultant. He also serves on the scientific advisory boards of privately held biotechnology firms and advises other venture capital companies.From 1982-1986, Dr. Kamen was with the biotechnology company Genetics Institute, Inc., where he played a leadership role in building the Cambridge, Mass. firm. While at Genetics Institute, he served as Director of Research, Vice President for Research and Senior Vice President, Scientific Affairs. He was responsible for discovery/pre-clinical research activities and established the clinical development department. Wyeth acquired Genetics Institute in 1991.Dr. Kamen graduated from Amherst College in 1965 with an A.B. (summa cum laude) in biophysics and from Harvard University in 1970 with a Ph.D. degree in biochemistry and molecular biology. After post-doctoral fellowships at the University of Zürich and at the Imperial Cancer Research Fund Laboratories, London, Dr. Kamen accepted a tenured appointment as senior staff scientist at the Imperial Cancer Research Fund Laboratories and served as head of its Transcription Laboratory until 1982. He is known for his fundamental academic contributions to the fields of gene expression, RNA stability, molecular virology, molecular oncology and human cytokines.
Back to OBP Team
|
|